Skip to content

Confocal Laser Endomicroscopy for Brain Tumors

Confocal Laser Endomicroscopy for Brain Tumors

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04280952
Acronym
CONVIVO
Enrollment
174
Registered
2020-02-21
Start date
2020-06-05
Completion date
2023-06-30
Last updated
2023-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Tumor, Convivo System, Laser Endomicroscopy, Surgery

Brief summary

The prognosis of glioblastoma patients highly depends on resection extent. Various strategies have been introduced to overcome the dilemma of intraoperative tumor identification. In gastroenterology, confocal laser endomicroscopy (CLE) allows precise differentiation of tumor tissue from surrounding mucosa in various diseases. Combining high-definition white light endoscopy with CLE significantly increases sensitivity and specificity compared with the sole application of high-definition white light endoscopy. CLE was recently introduced to neurosurgical applications. Although still in an early stage of clinical application, this technique has proven to be capable of differentiating various tumor entities in animal models as well as human tissue samples. CLE allows visualization of the underlying tissue on a microscopic scale, receiving information on the microstructure as well as cellular components. However, the clinical importance of this technique for its application in neurosurgery will be demonstrated in this clinical trial.

Detailed description

Background: The prognosis of glioblastoma patients highly depends on resection extent. Various strategies have been introduced to overcome the dilemma of intraoperative tumor identification. In gastroenterology, confocal laser endomicroscopy (CLE) allows precise differentiation of tumor tissue from surrounding mucosa in various diseases. Combining high-definition white light endoscopy with CLE significantly increases sensitivity and specificity compared with the sole application of high-definition white light endoscopy. CLE was recently introduced to neurosurgical applications. Although still in an early stage of clinical application, this technique has proven to be capable of differentiating various tumor entities in animal models as well as human tissue samples. CLE allows visualization of the underlying tissue on a microscopic scale, receiving information on the microstructure as well as cellular components. However, the clinical importance of this technique for its application in neurosurgery still needs to be demonstrated Methods: Intravenous injection dose of fluorescein sodium. For every operation the investigators plan to take pictures with the CONVIVO system before taking the material for standard frozen section and definitive histopathology. These pictures will be evaluated by a pathologist afterwards. Objectives: The primary objective of this trial is to demonstrate, that the CONVIVO system allows identification of tumor tissue. The secondary objectives are procedural aspects and handling issues covering the usability.

Interventions

DEVICECONVIVO

tumor tissue with the CONVIVO system

Sponsors

Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Tumor tissue identification with CONVIVO system

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The patient is undergoing neurosurgery for a suspected brain tumor and amenable to surgical resection by fluorescent guided technique * The patient has an indication for tumor resection * Macroscopic tumor visualization using sodium fluorescein is planned, concentration 5-10mg/kg * The patient is older than 18 years * Written consent

Exclusion criteria

* Stereotactic biopsy procedure * Patients with any kind of contraindication to the use of fluorescein sodium * Vulnerable persons (pregnant women, patients with Glasgow Coma Scale below 14) * Participation in other ongoing clinical trials with one exception: double inclusions are allowed provided that no interaction with NaF is to be expected * People who do not want to participate in the study * Tumors that do not exactly match the inclusion criteria * Emergency procedures in which no consent was obtained before the operation. * Multiple surgeries on the same patient.

Design outcomes

Primary

MeasureTime frameDescription
Identification of tumor tissueEnd of surgeryIdentification of tumor tissue versus non-affected tissue by the CONVIVO system in comparison to the histopathology of frozen section

Secondary

MeasureTime frameDescription
Accuracy of CONVIVO results14 days after surgeryAccuracy of CONVIVO results compared with results of final tumor histopathology
Time for tissue visualization with the CONVIVO systemEnd of surgeryIntraoperative time for the tissue visualization with the CONVIVO system
Rate of unclear visualizations14 days after surgeryRate of unclear visualizations in %

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026